Hans Salwender

Asklepios Klinik Altona — Germany

Medicine · Health Sciences

46h-index8.7kcitations250works5.12yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Multiple Myeloma Research and Treatments(177), Protein Degradation and Inhibitors(96), Cancer Treatment and Pharmacology(54), Peptidase Inhibition and Analysis(43), Acute Myeloid Leukemia Research(31)

Publications248 total

Daratumumab in severe Evans syndrome: a case report
Frontiers in Hematology·2026Open Access
Selinexor, Bortezomib and Dexamethasone After Sequential BCMA- and GPRC5D-Directed Therapy Failure in Penta-Refractory Multiple Myeloma: A Multicenter Real-World Analysis
2025Open Access
Prognostic Impact of the Hevylite Assay in Patients With <scp>IgG</scp> or <scp>IgA</scp> Multiple Myeloma Treated Within the <scp>GMMG</scp> ‐ <scp>MM5</scp> Trial
European Journal Of Haematology·2025Open Access
Peripheral residual disease activity assessment by MALDI-TOF mass spectrometry in patients with newly-diagnosed multiple myeloma in the GMMG-HD7 study
Blood·2025Open Access
Prospective systematic classification of causes of death in the course of multiple myeloma
Blood Cancer Journal·2025Open Access
Machine learning risk stratification strategy for multiple myeloma: Insights from the EMN–HARMONY Alliance platform
HemaSphere·2025Open Access
Post-Induction Outcomes and Updated Minimal Residual Disease Analysis from GMMG-HD10/DSMM-XX (MajesTEC-5): A Study of Teclistamab-Based Induction Regimens in Newly Diagnosed Multiple Myeloma (NDMM)
Clinical Lymphoma Myeloma & Leukemia·2025
Insights from Cytogenetic Subgroup Analyses in the GMMG-CONCEPT trial with Isa-KRd in High-Risk Newly Diagnosed Multiple Myeloma
Clinical Lymphoma Myeloma & Leukemia·2025
Klinische Erfahrungen und Expertenempfehlungen zum Einsatz von Selinexor in der Therapie des Multiplen Myeloms
TumorDiagnostik & Therapie·2025
Cardiac biomarkers for risk stratification in newly diagnosed high-risk multiple myeloma in the GMMG-CONCEPT trial
Cardio-Oncology·2025· 1 citedOpen Access
Venetoclax or placebo in combination with bortezomib and dexamethasone in relapsed or refractory multiple myeloma (BELLINI): final overall survival results from a randomised, phase 3 study
The Lancet Haematology·2025· 1 cited
Lenalidomide in combination with rituximab, dexamethasone, high-dose ARA-C and cisplatinum as salvage therapy in refractory or relapsed aggressive B-cell non-hodgkin-lymphoma - an open-label, multicentre phase I/II study (DSHNHL-R6)
Annals of Hematology·2025Open Access
Biomarker microRNA-371a-3p - expression in malignancies other than germ-cell tumours
Journal of Cancer Research and Clinical Oncology·2025· 1 citedOpen Access
Salvage autologous transplant in relapsed multiple myeloma: long-term follow-up of the phase 3 GMMG ReLApsE trial
Blood·2025· 12 citedOpen Access
Lenalidomide in combination with Rituximab, Dexamethasone, High-dose ARA-C and Cisplatinum as Salvage Therapy in Refractory or Relapsed Aggressive B-cell Non-Hodgkin-Lymphoma - An open-label, multicentre phase I/II study (DSHNHL-R6)
2024Open Access
Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone Induction Therapy for Transplant-Eligible Newly Diagnosed Multiple Myeloma: Final Part 1 Analysis of the GMMG-HD7 Trial
Journal of Clinical Oncology·2024· 49 citedOpen Access
Single Vs. Tandem Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Real-World Multi-Center Study from the German Registry for Hematopoietic Stem Cell Transplantation and Cell Therapy (DRST)
Blood·2024· 1 cited
Development and Validation of Novel Machine Learning-Based Risk Scores for Multiple Myeloma: Insights from the Harmony Alliance Big Data Platform
Blood·2024Open Access
Early Relapse in Patients with Newly-Diagnosed Multiple Myeloma: A European Myeloma Network/Harmony Alliance Analysis Including 10843 Patients
Blood·2024· 3 citedOpen Access
Long-Term Follow-up Analysis of Progression-Free and Overall Survival in Newly Diagnosed Multiple Myeloma Patients from the GMMG Myeloma Registry Following the Randomized Phase III GMMG-HD6 Trial
Blood·2024Open Access
page 1 of 13Next →

Frequent Co-authors

Hartmut Goldschmidt(24), Katja Weisel(19), Igor Wolfgang Blau(15), Axel Benner(14), Uta Bertsch(13), Christof Scheid(11), Dirk Hose(10), Anna Jauch(10), Katharina S. Götze(10), Konstanze Döhner(10), Hartmut Döhner(10), Mathias Hänel(10), Pieter Sonneveld(9), Marc S. Raab(9), Thomas Hielscher(8), Richard F. Schlenk(8), Markus Munder(8), Ingo Schmidt‐Wolf(7), Bronno van der Holt(7), Sonja Zweegman(7)